FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Gastrointestinal stromal tumours (GISTs) are fairly rare neoplasms, constituting less than 3 % of all gastrointestinal malignancies. The integration of molecularly targeted treatment regimes (i.e., tyrosine kinase inhibitors) in clinical oncology has revolutionized the management of patients with irresectable GISTs or metastatic disease. Malignant GISTs usually display increased glucose metabolism and therefore (18)F-fluorodeoxyglucose (FDG) uptake within the scope of positron emission tomography (PET) scans. Nowadays, dual-modality FDG PET/CT (computed tomography) imaging is of considerable value in diagnostic work-up of patients with GISTs acquiring functional and anatomic information simultaneously. The following article sheds light on the impact of FDG PET and combined FDG PET/CT imaging in initial disease evaluation, detection of tumour recurrence and the early assessment of treatment response to molecularly targeted agents such as imatinib mesylate or sunitinib maleate.
Department of Nuclear Medicine and Endocrinology, PET-CT Center Klagenfurt, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020 Klagenfurt, Austria. philipp.malle@kabeg.at
Philipp
P
Malle
Manfred
M
Sorschag
Hans-Jürgen
HJ
Gallowitsch
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D019788:Fluorodeoxyglucose F18; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging* / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D007211:Indoles / Q000627:therapeutic use; D058990:Molecular Targeted Therapy / Q000379:methods; D064847:Multimodal Imaging / Q000379:methods*; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D010879:Piperazines / Q000627:therapeutic use; D049268:Positron-Emission Tomography / Q000379:methods*; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D000077210:Sunitinib; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D001786:Blood Glucose; D007211:Indoles; D010879:Piperazines; D011743:Pyrimidines; D011758:Pyrroles; D019788:Fluorodeoxyglucose F18; D000068877:Imatinib Mesylate; D000077210:Sunitinib